Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: a randomized clinical trial
The EMPAVR study was registered in December 2024 (Clinical Trial Registration number: NCT06171802) before enrollment of the first patient. All patients will provide oral and written informed consent. The EMPAVR study is approved by the Regional Committee on Health Research Ethics and the Danish Medicines Agency.
Authors
- Eva Havers-Borgersen
- Gintautas Bieliauskas (ORCID: https://orcid.org/0000-0002-4509-6654)
- Louise Marqvard Sørensen (ORCID: https://orcid.org/0009-0007-1235-9001)
- Jeppe Kofoed Petersen (ORCID: https://orcid.org/0000-0002-1166-7877)
- Jesper J. Linde (ORCID: https://orcid.org/0000-0002-2101-5098)
- M Reinert
- Kristina Procida
- Jørgen Tobias Kühl
- Klaus Fuglsang Kofoed
- Ole de Backer
- Anna Axelsson Raja
- Emil Fosbøl
- Lars Køber
- Emma Louise Ries Møller
- Morten Schou
- Jesper Jensen
Institutions
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Zealand University Hospital (DK)
Publication Details
- Journal
- American Heart Journal
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.ahj.2026.107432
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00